Translational biomedical research integrates pharmacology, toxicology, and omics-based approaches to address major challenges in human health. Current work focuses on biomarker discovery for early cancer detection, particularly cholangiocarcinoma, using proteomics and metabolomics platforms. In parallel, efforts are directed toward the development and validation of innovative point-of-care diagnostic technologies, including electrochemical biosensors for quantitative detection of glycated hemoglobin (HbA1c). Additional research explores pharmacogenomics and genetic polymorphisms influencing drug response, especially in malaria and cancer, as well as systematic evaluations of drug metabolism in anticancer medicinal plants. Investigations into natural products further examine their antiproliferative and anti-inflammatory properties and their potential interactions with conventional therapies. Environmental toxicology studies address the impact of chronic cadmium exposure on renal function and molecular stress responses. Collectively, this body of work aims to bridge molecular mechanisms with clinical applications to advance disease diagnosis, therapeutic strategies, and public health outcomes.